ESPR Esperion Therapeutics, Inc.

25.00
+1.81  (7.81%)
Previous Close 23.19
Open 23.24
Price To book 2.06
Market Cap 563.83M
Shares 22,553,000
Volume 1,817,546
Short Ratio 11.12
Av. Daily Volume 430,800

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 (PK/PD) top-line data met primary endpoint - October 2016.
Bempedoic acid (ETC-1002-035)
Patients treated with high-dose statin therapy
Phase 3 initiation of efficacy trials announced January 8, 2017. Data due mid 2018.
Bempedoic acid - CLEAR LDL-C Lowering Program 1002-046, 1002-047 and 1002-048
Hypercholesterolemia - statin intolerance
Phase 3 long-term safety and tolerability trial initiated January 2016. Completion of enrollment announced January 25, 2017. Top-line results due 2Q 2018.
Bempedoic acid (ETC-1002-040)
Hyperlipidemia whose LDL-C is not adequately controlled with low- and moderate-dose statins
Phase 2 data released July 2015
Bempedoic acid ETC-1002-014
Hypercholesterolemia and hypertension

Latest News

  1. Esperion to Participate in Fireside Chat at RBC Capital Markets Global Healthcare Conference
  2. Esperion Positioned to Capitalize on Phase III Trials
  3. Harry Boxer’s stocks to watch: biotechnology and technology
  4. Four Biotech Stocks Breaking Out
  5. What’s Next For Esperion Therapeutics Inc (ESPR)?
  6. Mergers & Acquisitions Could be a Key Catalyst Sending These Biotech Stocks to New Highs in 2017
  7. Why Esperion Therapeutics, Inc. Is Soaring Today
  8. Esperion Completes Enrollment of Pivotal Phase 3 Long-Term Safety and Tolerability Study of Bempedoic Acid in Patients with Hypercholesterolemia
  9. ESPERION THERAPEUTICS, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits
  10. Esperion Announces Initiation of Global Cardiovascular Outcomes Trial for Bempedoic Acid
  11. Esperion Announces Initiation of Three Pivotal Phase 3 Studies for Bempedoic Acid
  12. Esperion to Present at the 35th Annual J.P. Morgan Healthcare Conference
  13. Esperion Therapeutics Inc (ESPR): Smart Money Doubles Down
  14. ESPERION THERAPEUTICS, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and E
  15. Amgen, Regeneron 2017 LDL-Busters Could Boost This Small-Cap Biotech
  16. Esperion Therapeutics, Inc. :ESPR-US: Earnings Analysis: Q3, 2016 By the Numbers : November 29, 2016
  17. Esperion Therapeutics Announces Publication of Definitive Paper on Bempedoic Acid Mechanism of Action in Nature Communications
  18. ESPERION THERAPEUTICS, INC. Financials
  19. ESPERION THERAPEUTICS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements a
  20. ESPERION THERAPEUTICS, INC. Files SEC form 10-Q, Quarterly Report
  21. Esperion Therapeutics Provides Bempedoic Acid Development Program Updates; Reports Third Quarter 2016 Financial Results
  22. Esperion Therapeutics to Present at the Credit Suisse 25th Annual Healthcare Conference
  23. Credit Suisse Changes Its View On Esperion Therapeutics, Raises Price Target
  24. Bempedoic Acid Global Phase 3 Clinical Program to Include Patients on Any Statin at Any Dose
  25. ESPERION THERAPEUTICS, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits
  26. Esperion Therapeutics Provides Bempedoic Acid Development Program Updates; Reports Second Quarter 2016 Financial Results
  27. Esperion Therapeutics Provides Clinical Development and Regulatory Update for Bempedoic Acid
  28. Esperion Therapeutics Provides Bempedoic Acid Development Program Updates; Reports First Quarter 2016 Financial Results